ES2722773T3 - Polipéptidos de fHbp meningocócicos modificados - Google Patents

Polipéptidos de fHbp meningocócicos modificados Download PDF

Info

Publication number
ES2722773T3
ES2722773T3 ES15738352T ES15738352T ES2722773T3 ES 2722773 T3 ES2722773 T3 ES 2722773T3 ES 15738352 T ES15738352 T ES 15738352T ES 15738352 T ES15738352 T ES 15738352T ES 2722773 T3 ES2722773 T3 ES 2722773T3
Authority
ES
Spain
Prior art keywords
seq
polypeptide
meningococcal fhbp
fhbp polypeptides
modified meningococcal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15738352T
Other languages
English (en)
Inventor
Matthew Bottomley
Vega Masignani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of ES2722773T3 publication Critical patent/ES2722773T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

Un polipéptido que comprende una secuencia de aminoácidos que tiene al menos un 80 % de identidad de secuencia con la SEQ ID NO: 5, en el que (a) la secuencia de aminoácidos difiere de la SEQ ID NO: 5 en los restos 123 y 240 con respecto a la SEQ ID NO:5; (b) el polipéptido puede, después de la administración a un ser humano, generar anticuerpos que pueden reconocer un polipéptido que consiste en la SEQ ID NO: 4; (c) el polipéptido tiene una mayor estabilidad que un polipéptido que consiste en la SEQ ID NO: 4; y (d) el polipéptido tiene una menor afinidad para fH humano que un polipéptido que consiste en la SEQ ID NO: 4.
ES15738352T 2014-07-17 2015-07-16 Polipéptidos de fHbp meningocócicos modificados Active ES2722773T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14177564 2014-07-17
PCT/EP2015/066228 WO2016008960A1 (en) 2014-07-17 2015-07-16 Modified meningococcal fhbp polypeptides

Publications (1)

Publication Number Publication Date
ES2722773T3 true ES2722773T3 (es) 2019-08-16

Family

ID=51178812

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15738352T Active ES2722773T3 (es) 2014-07-17 2015-07-16 Polipéptidos de fHbp meningocócicos modificados

Country Status (18)

Country Link
US (2) US11066450B2 (es)
EP (1) EP3169357B1 (es)
JP (1) JP2017522320A (es)
KR (1) KR20170023191A (es)
CN (1) CN106795208A (es)
AR (1) AR102324A1 (es)
AU (1) AU2015289192A1 (es)
BE (1) BE1022641B1 (es)
BR (1) BR112017000521A2 (es)
CA (1) CA2954745A1 (es)
EA (1) EA201692552A1 (es)
ES (1) ES2722773T3 (es)
IL (1) IL249822A0 (es)
MX (1) MX2017000776A (es)
SG (1) SG11201610945PA (es)
TR (1) TR201901062T4 (es)
WO (1) WO2016008960A1 (es)
ZA (1) ZA201700170B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2552942B1 (en) 2010-03-30 2017-12-27 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
LT3110442T (lt) * 2014-02-28 2020-12-28 Glaxosmithkline Biologicals Sa Modifikuoti meningokokinio fhbp polipeptidai
TR201901062T4 (tr) * 2014-07-17 2019-02-21 Glaxosmithkline Biologicals Sa Modifiye meningokokal fhbp polipeptidleri.
EA038940B1 (ru) 2014-07-17 2021-11-12 Глаксосмитклайн Байолоджикалс С.А. Менингококковые вакцины
KR20170028442A (ko) * 2014-07-23 2017-03-13 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
HUE052751T2 (hu) * 2016-11-25 2021-05-28 Glaxosmithkline Biologicals Sa Natív OMV-antigén konjugátumok és alkalmazásuk
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
WO2021126421A1 (en) 2019-12-19 2021-06-24 Dow Technology Investments Llc Processes for preparing isoprene and mono-olefins comprising at least six carbon atoms
KR20230147075A (ko) 2021-02-19 2023-10-20 사노피 파스퇴르 인크 수막구균 b 재조합 백신
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024030931A1 (en) 2022-08-03 2024-02-08 Sanofi Pasteur Inc. Adjuvanted immunogenic composition against neisseria meningitidis b

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
EP1897555B1 (en) 2000-01-17 2014-07-16 Novartis Vaccines and Diagnostics S.r.l. Supplemented OMV vaccine against meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
BR112012010531A2 (pt) * 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
CN102869377A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
EP2552942B1 (en) 2010-03-30 2017-12-27 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
GB201120634D0 (en) 2011-11-30 2012-01-11 Univ Sheffield Adjuvant polypeptide
AU2013276083B2 (en) 2012-06-14 2018-04-05 Institut Pasteur Vaccines for serogroup X meningococcus
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
LT3110442T (lt) 2014-02-28 2020-12-28 Glaxosmithkline Biologicals Sa Modifikuoti meningokokinio fhbp polipeptidai
TR201901062T4 (tr) 2014-07-17 2019-02-21 Glaxosmithkline Biologicals Sa Modifiye meningokokal fhbp polipeptidleri.
EA038940B1 (ru) 2014-07-17 2021-11-12 Глаксосмитклайн Байолоджикалс С.А. Менингококковые вакцины

Also Published As

Publication number Publication date
AR102324A1 (es) 2017-02-22
KR20170023191A (ko) 2017-03-02
JP2017522320A (ja) 2017-08-10
SG11201610945PA (en) 2017-01-27
US11066450B2 (en) 2021-07-20
US20220002355A1 (en) 2022-01-06
EP3169357A1 (en) 2017-05-24
AU2015289192A1 (en) 2017-02-02
ZA201700170B (en) 2019-06-26
EA201692552A1 (ru) 2017-06-30
BE1022641B1 (fr) 2016-06-23
IL249822A0 (en) 2017-03-30
CN106795208A (zh) 2017-05-31
BR112017000521A2 (pt) 2017-11-21
MX2017000776A (es) 2017-05-04
BE1022641A1 (fr) 2016-06-23
US11939357B2 (en) 2024-03-26
US20170226161A1 (en) 2017-08-10
CA2954745A1 (en) 2016-01-21
TR201901062T4 (tr) 2019-02-21
WO2016008960A1 (en) 2016-01-21
EP3169357B1 (en) 2018-11-07

Similar Documents

Publication Publication Date Title
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
PE20190335A1 (es) Receptores de celulas t
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
MX2018001213A (es) Nuevos metodos para inducir una respuesta inmunitaria.
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
EA201792245A1 (ru) Биоконъюгаты и их применения
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
CL2017003228A1 (es) Fragmentos mutantes de proteína ras
ES2671434T3 (es) Antagonistas de Kv1.3 y métodos de uso
UY36565A (es) Variantes de polipéptidos que dividen toxinas de fusarium, aditivo que contiene estas variantes y su uso, asi como procedimientos para la division de toxinas de fusarium
BR112016016103A2 (pt) Composição de antígenos micobacterianos
CO2017012675A2 (es) Péptidos lipidados resistentes a proteasas
MX2016014633A (es) Nuevos derivados de cath2.
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
PH12015502100A1 (en) Reducing the risk of autoimmune disease
NZ744289A (en) Composition containing amino acids
PH12015502037A1 (en) Activating adiponectin by casein hydrolysate
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy